LinkedIn facebook twitter youtube

iconTel: 027-85558552

iconE-mail: Marketing@circlestar-chem.com

Product Introduction:

Description Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].

Related products

027-85558552 8613437180835 Marketing@circlestar-chem.com